![Emil Chuang](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Emil Chuang
Directeur Technique/Scientifique/R&D chez Intrinsic Medicine, Inc.
Profil
Emil Chuang is currently the Chief Medical Officer at Intrinsic Medicine, Inc. He previously held the same position at the same company.
Prior to that, he was the Global Head-Translational Research at Takeda Pharmaceutical Co., Ltd.
from 2016 to 2018.
From 2018 to 2020, he was the Vice President-Precision Medicine at Biora Therapeutics, Inc. Chuang completed his undergraduate degree at The University of Sydney.
Postes actifs de Emil Chuang
Sociétés | Poste | Début |
---|---|---|
Intrinsic Medicine, Inc.
![]() Intrinsic Medicine, Inc. Miscellaneous Commercial ServicesCommercial Services Intrinsic Medicine, Inc. operates as a therapeutics company leveraging human milk biology to create new medicines to transform gut-brain axis (GBA) disorders with large populations underserved by current treatment options. The company was founded by Alexander Martinez and Jason Ferrone in August, 2018 and is headquartered in Seattle, WA. | Directeur Technique/Scientifique/R&D | 01/09/2021 |
Anciens postes connus de Emil Chuang
Sociétés | Poste | Fin |
---|---|---|
BIORA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/12/2020 |
TAKEDA PHARMACEUTICAL COMPANY LIMITED | Corporate Officer/Principal | 01/06/2018 |
Formation de Emil Chuang
The University of Sydney | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
BIORA THERAPEUTICS, INC. | Health Services |
TAKEDA PHARMACEUTICAL COMPANY LIMITED | Health Technology |
Entreprise privées | 1 |
---|---|
Intrinsic Medicine, Inc.
![]() Intrinsic Medicine, Inc. Miscellaneous Commercial ServicesCommercial Services Intrinsic Medicine, Inc. operates as a therapeutics company leveraging human milk biology to create new medicines to transform gut-brain axis (GBA) disorders with large populations underserved by current treatment options. The company was founded by Alexander Martinez and Jason Ferrone in August, 2018 and is headquartered in Seattle, WA. | Commercial Services |